Nasdaq · CIK 0001615219
DCOY Salarius Pharmaceuticals, Inc.
Insider trading from SEC Form 4. Last filing 41 d ago. Close $1.47 on Oct 9, 2026, 0% from the 52-week low and -97% from the high.
Last 90 days
Net insider value
$0
no open-market trades
Buys
0
$0 by 0 insiders
Sells
0
$0 by 0 insiders
Insiders on file
10
with a Form 4 at this company
Price and insider trades, last year
DCOYOct 9, 2026 · close 1.47
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
Open-market buys and sells at Salarius Pharmaceuticals, Inc., scored.
| Score | Insider | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 15Weak | Arnold C Hanish director sell | $17 27 shares | -1% | +2% from low-99% from high | |
| 33Weak | Arnold C Hanish director buy | $3,741 5,000 shares | first purchase | - | |
| 40Moderate | Mark J Rosenblum Exec VP Finance, CFO buy | $16k 20,000 shares | first purchase | - |
Transactions
The last 14 rows filed, every code.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Aug 31, 2026 | Tess Burleson director | AGrant or award Common Stock | +2,000 | $0.00 | $0 | 2,002 | 41 d ago |
| Aug 31, 2026 | Jonathan I Lieber director | AGrant or award Common Stock | +2,000 | $0.00 | $0 | 2,002 | 41 d ago |
| Aug 31, 2026 | Frederick Pierce II Chief Executive Officer | AGrant or award Common Stock | +33,455 | $0.00 | $0 | 34,844 | 41 d ago |
| Aug 31, 2026 | Arnold C Hanish director | AGrant or award Common Stock | +3,000 | $0.00 | $0 | 3,418 | 41 d ago |
| Aug 31, 2026 | Mark J Rosenblum Chief Financial Officer | AGrant or award Common Stock | +9,682 | $0.00 | $0 | 11,363 | 41 d ago |
| Aug 31, 2026 | Paul Lammers director | AGrant or award Common Stock | +2,000 | $0.00 | $0 | 2,001 | 41 d ago |
| Aug 31, 2026 | William K. McVicar director | AGrant or award Common Stock | +3,000 | $0.00 | $0 | 3,002 | 41 d ago |
| Aug 31, 2026 | Barbara Louise Hibner Chief Scientific Officer | AGrant or award Common Stock | +4,216 | $0.00 | $0 | 4,216 | 41 d ago |
| Aug 31, 2026 | Peter Klaus Marschel Chief Business Officer | AGrant or award Common Stock | +3,900 | $0.00 | $0 | 3,900 | 41 d ago |
| Aug 31, 2026 | Patricia G. Gauthier director | AGrant or award Common Stock | +2,000 | $0.00 | $0 | 2,000 | 41 d ago |
| Dec 30, 2025 | Arnold C Hanish director | SOpen-market sale Common Stockindirect: By Arnold C. Hanish Trust | -15 | $0.64 | $10 | 5,000 | Jan 2, 2026 |
| Dec 30, 2025 | Arnold C Hanish director | SOpen-market sale Common Stock | -12 | $0.64 | $8 | 0 | Jan 2, 2026 |
| Nov 20, 2025 | Arnold C Hanish director | POpen-market purchase Common Stockindirect: By Arnold C. Hanish Trust | +5,000 | $0.75 | $3,741 | 5,015 | Nov 24, 2025 |
| Nov 20, 2025 | Mark J Rosenblum Exec VP Finance, CFO | POpen-market purchase Common Stock | +20,000 | $0.80 | $16k | 20,177 | Nov 20, 2025 |
Insiders
Everyone who has filed a Form 4 here.
- Tess Burlesondirector
- Patricia G. Gauthierdirector
- Arnold C Hanishdirector
- Barbara Louise HibnerChief Scientific Officer
- Paul Lammersdirector
- Jonathan I Lieberdirector, cfo, officer
- Peter Klaus MarschelChief Business Officer
- William K. McVicardirector
- Frederick Pierce IIChief Executive Officer
- Mark J RosenblumExec VP Finance, CFO
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.